Anti-VEGF-A affects the angiogenic properties of tumor-derived microparticles

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Munster, Michal ^a   Fremder, Ella ^a   Miller, Valeria ^a   Ben Tsedek, Neta ^a   Davidi, Shiri ^a   Scherer, Stefan J ^b   Shaked, Yuval ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

B20 ANTIBODY; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN ANTIBODY; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; MONOCLONAL ANTIBODY;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; AORTA; ARTICLE; BONE MARROW CELL; BONE MARROW DERIVED PRO ANGIOGENIC CELL; BREAST CARCINOMA; CANCER TISSUE; CAPILLARY DENSITY; CARCINOMA CELL; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MEMBRANE MICROPARTICLE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR DERIVED MICROPARTICLE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; ANIMAL; CELL MOTION; CYTOLOGY; DRUG EFFECTS; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL MOVEMENT; CELL-DERIVED MICROPARTICLES; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84899696815     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0095983     Document Type: Article

References (41)

1. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, et al. (1992) Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma. Journal National Cancer Institute 84: 1875-1887. (Pubitemid 23004615)
2. Folkman J (1985) Tumor angiogenesis. Advances in Cancer Research 43: 175-203.
3. Folkman J, Watson K, Ingber D, Hanahan D (1989) Induction of angiogenesis during transition from hyperplasia to neoplasia. Nature 339: 58-61. (Pubitemid 19115892)
4. Shaked Y, Voest EE (2009) Bone marrow derived cells in tumor angiogenesis and growth: are they the good, the bad or the evil? BiochimBiophysActa 1796: 1-4.
5. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, et al. (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science 275: 964-967. (Pubitemid 27087709)
6. Kerbel RS (2008) Tumor angiogenesis. New England Journal of Medicine 358: 2039-2049.
7. Horrevoets AJ (2009) Angiogenic monocytes: another colorful blow to endothelial progenitors. AmJ Pathol 174: 1594-1596.
8. Gao D, Nolan D, McDonnell K, Vahdat L, Benezra R, et al. (2009) Bone marrow-derived endothelial progenitor cells contribute to the angiogenic switch in tumor growth and metastatic progression. BiochimBiophysActa 1796: 33-40.
9. Purhonen S, Palm J, Rossi D, Kaskenpaa N, Rajantie I, et al. (2008) Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth. ProcNatlAcadSciUSA 105: 6620-6625. (Pubitemid 351754556)
10. Shaked Y, Ciarrocchi A, Franco M, Lee CR, Man S, et al. (2006) Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 313: 1785-1787. (Pubitemid 44454154)
11. Shaked Y, Henke E, Roodhart JM, Mancuso P, Langenberg MH, et al. (2008) Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 14: 263-273.
12. De Palma M, Lewis CE (2013) Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 23: 277-286.
13. Welford AF, Biziato D, Coffelt SB, Nucera S, Fisher M, et al. (2011) TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice. JClinInvest 121: 1969-1973.
14. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, et al. (2011) Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 1: 54-67.
15. Kim JJ, Tannock IF (2005) Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer 5: 516-525. (Pubitemid 40942828)
16. Shaked Y, Kerbel RS (2007) Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy. Cancer Res 67: 7055-7058. (Pubitemid 47206528)
17. Toth B, Liebhardt S, Steinig K, Ditsch N, Rank A, et al. (2008) Platelet-derived microparticles and coagulation activation in breast cancer patients. Thromb Haemost 100: 663-669.
18. Toth B, Lok CA, Boing A, Diamant M, van der Post JA, et al. (2007) Microparticles and exosomes: impact on normal and complicated pregnancy. Am J Reprod Immunol 58: 389-402. (Pubitemid 47534849)
19. Mostefai HA, Andriantsitohaina R, Martinez MC (2008) Plasma membrane microparticles in angiogenesis: role in ischemic diseases and in cancer. Physiol Res 57: 311-320.
20. Rak J (2010) Microparticles in cancer. SeminThrombHemost 36: 888-906.
21. Al-Nedawi K, Meehan B, Micallef J, Lhotak V, May L, et al. (2008) Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol 10: 619-624. (Pubitemid 351627382)
22. Fremder E, Munster M, Aharon A, Miller V, Gingis-Velitski S, et al. (2013) Tumor-derived microparticles induce bone marrow-derived cell mobilization and tumor homing: A process regulated by osteopontin. Int J Cancer.
23. Cahan MA, Walter KA, Colvin OM, Brem H (1994) Cytotoxicity of taxol in vitro against human and rat malignant brain tumors. Cancer Chemother-Pharmacol 33: 441-444. (Pubitemid 24057699)
24. Liang WC, Wu X, Peale FV, Lee CV, Meng YG, et al. (2006) Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem 281: 951-961.
25. Boilard E, Nigrovic PA, Larabee K, Watts GF, Coblyn JS, et al. (2010) Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science 327: 580-583.
26. Gingis-Velitski S, Loven D, Benayoun L, Munster M, Bril R, et al. (2011) Host response to short-term, single-agent chemotherapy induces matrix metalloproteinase-9 expression and accelerates metastasis in mice. Cancer Res 71: 6986-6996.
27. Adini A, Fainaru O, Udagawa T, Connor KM, Folkman J, et al. (2009) Matrigel cytometry: a novel method for quantifying angiogenesis in vivo. J ImmunolMethods 342: 78-81.
28. Shaked Y, Bertolini F, Man S, Rogers MS, Cervi D, et al. (2005) Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis: implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 7 101-111. (Pubitemid 40126386)
29. van der Pol E, Hoekstra AG, Sturk A, Otto C, van Leeuwen TG, et al. (2010) Optical and non-optical methods for detection and characterization of microparticles and exosomes. J Thromb Haemost 8: 2596-2607.
30. Bertolini F, Shaked Y, Mancuso P, Kerbel RS (2006) The multifaceted circulating endothelial cell in cancer: from promiscuity to surrogate marker and target identification. Nature Rev Cancer 6: 835-845. (Pubitemid 44629895)
31. Shojaei F, Wu X, Malik AK, Zhong C, Baldwin ME, et al. (2007) Tumor refractoriness to anti-VEGF treatment is mediated by CD11b(+)Gr1(+) myeloid cells. Nat Biotechnol 25: 911-920. (Pubitemid 47236916)
32. Shaked Y, Tang T, Woloszynek J, Daenen LG, Man S, et al. (2009) Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents. Cancer Res 69: 7524-7528.
33. Voloshin T, Voest EE, Shaked Y (2013) The host immunological response to cancer therapy: An emerging concept in tumor biology. Experimental cell research.
34. Hajrasouliha AR, Jiang G, Lu Q, Lu H, Kaplan HJ, et al. (2013) Exosomes from retinal astrocytes contain antiangiogenic components that inhibit laser-induced choroidal neovascularization. J Biol Chem 288: 28058-28067.
35. Sinauridze EI, Kireev DA, Popenko NY, Pichugin AV, Panteleev MA, et al. (2007) Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets. Thromb Haemost 97: 425-434. (Pubitemid 46437805)
36. Aharon A, Tamari T, Brenner B (2008) Monocyte-derived microparticles and exosomes induce procoagulant and apoptotic effects on endothelial cells. Thromb Haemost 100: 878-885.
37. Videira PA, Piteira AR, Cabral MG, Martins C, Correia M, et al. (2011) Effects of bevacizumab on autocrine VEGF stimulation in bladder cancer cell lines. UrolInt 86: 95-101.
38. Verheul HM, Lolkema MP, Qian DZ, Hilkes YH, Liapi E, et al. (2007) Platelets take up the monoclonal antibody bevacizumab. ClinCancer Res 13: 5341-5347. (Pubitemid 47510358)
39. Bertolini F, Marighetti P, Shaked Y (2010) Cellular and soluble markers of tumor angiogenesis: from patient selection to the identification of the most appropriate postresistance therapy. BiochimBiophysActa 1806: 131-137.
40. Benayoun L, Gingis-Velitski S, Voloshin T, Segal E, Segev R, et al. (2012) Tumor-initiating cells of various tumor types exhibit differential angiogenic properties and react differently to antiangiogenic drugs. Stem Cells 30: 1831-1841.
41. Baran J, Baj-Krzyworzeka M, Weglarczyk K, Szatanek R, Zembala M, et al. (2010) Circulating tumour-derived microvesicles in plasma of gastric cancer patients. Cancer Immunol Immunother 59: 841-850.